跳至主要内容
临床试验/ISRCTN11568655
ISRCTN11568655进行中(未招募)未知

on-interventional study to capture data on the use of a VWF/FVIII concentrate (wilate®) in all clinical settings of von Willebrand disease including health-related quality of life

Octapharma GmbH0 个研究点目标入组 120 人开始时间: 2022年2月9日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. The patient has congenital or acquired Von Willebrand disease (VWD) and requires injections with VWF-containing concentrate (wilate)
  • 2. With a positive bleeding history, other possible causes have been excluded

排除标准

  • 1. Patients with known contraindications as specified in the Summary of Product Characteristics (SPC)
  • 2. The patient could actually be treated with DDAVP (Desmopressin Acetate)
  • 3. The patient has a von Willebrand factor activity over 70% and there are no findings manifesting the VWD diagnosis

研究者

相似试验

Collection of data on the use of a VWF/FVIII... | 临床试验